Vous êtes ici : Accueil > Detection of glioblastoma response to temozolomide combined with bevacizumab based on mu MRI and mu PET imaging reveals [F-18]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy

publications-2011-2015

Detection of glioblastoma response to temozolomide combined with bevacizumab based on mu MRI and mu PET imaging reveals [F-18]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy

Publié le 19 mars 2015
Detection of glioblastoma response to temozolomide combined with bevacizumab based on mu MRI and mu PET imaging reveals [F-18]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy
Auteurs
Corroyer-Dulmont A, Peres EA, Petit E, Guillamo JS, Varoqueaux N, Roussel S, Toutain J, Divoux D, MacKenzie ET, Delamare J, Ibazizene M, Lecocq M, Jacobs AH, Barre L, Bernaudin M, Valable S
Revue
InstitutI2BM
Année2 013

Go back to list